19 November 2026 Sydney, Australia

Nyrada Annual General Meeting Results

Nyrada Inc. (ASX:NYR), a clinical-stage biotechnology company focused on developing Transient Receptor Potential Canonical (TRPC) ion channel inhibitors to treat a range of medical conditions, announces the results of today's Annual General Meeting.

All resolutions were passed and decided by way of a poll.

The results are set out in the attached document, in accordance with ASX Listing Rule 3.13.2 and Section 251AA(2) of the Corporations Act.

-ENDS-

Nyrada Inc. Level 22/23, Salesforce Tower, 180 George Street, Sydney NSW 2000 ARBN 625 401 818

About Xolatryp®

Xolatryp is a small-molecule inhibitor of TRPC3/6/7 channels designed to limit excessive Ca^{2+} entry related to multiple disease pathologies.

A Phase I clinical trial to assess the safety, tolerability, and pharmacokinetics has been successfully completed and a Phase IIa clinical trial has commenced to assess the safety and preliminary efficacy of Xolatryp in reducing cardiac reperfusion injury in patients with ST-Elevation Myocardial Infarction (STEMI) undergoing percutaneous coronary intervention (PCI).

Key Links:

Cardioprotection

- PROTECT-MI website - https://www.protect-mi.com
- PROTECT-MI NIH Entry - https://bit.ly/4cB2fF9
- FDA IND Feedback - https://bit.ly/4zyu9dZ
- Phase IIa factsheet - https://bit.ly/4bcDlKj
- Preclinical cardioprotection study 1a - https://bit.ly/4sigwMZ
- Preclinical cardioprotection study 1b - https://bit.ly/4rmOsXn
- Preclinical cardioprotection study 2 - https://bit.ly/40jHpUg

Oncology

- Preclinical cardiomyopathy study - https://bit.ly/4yR9BgD
- Preclinical cardiomyopathy pilot study - https://bit.ly/4xJH3Fj
- Preclinical anti-tumour study - https://bit.ly/49rWOa0

Neuroprotection

- Preclinical traumatic brain injury study - https://bit.ly/40fhrRT
- Preclinical stroke study - https://bit.ly/4sygHmH

Foundations

- US Patent Grant - https://bit.ly/4yUqMyf
- Phase I results - https://bit.ly/3Nt0GzH
- Preclinical mitochondria stabilisation study - https://bit.ly/4yiZUHa
- GLP study results - https://bit.ly/4d8VYkX
- CSANZ Conference Poster - https://bit.ly/4A9ROmf

Corporate

- Latest presentation slides - https://bit.ly/3VAM45k

Nyrada Inc. Level 22/23, Salesforce Tower, 180 George Street, Sydney NSW 2000 ARBN 625 401 818

About Nyrada Inc.

Nyrada Inc. is a clinical stage biotechnology company focused on the discovery and development of innovative small-molecule therapies, specifically targeting Transient Receptor Potential Canonical (TRPC) ion channels. The company's lead candidate, Xolatryp®, has shown efficacy in preclinical cardioprotection, neuroprotection, and oncology models and has completed a first-in-human Phase I clinical trial. A Phase IIa clinical trial has commenced to assess the safety and preliminary efficacy of Xolatryp in reducing cardiac reperfusion injury in patients with ST-Elevation Myocardial Infarction (STEMI) undergoing PCI. Nyrada Inc. (ARBN 625 401 818) is incorporated in Delaware, US, with limited liability for its stockholders.

www.nyrada.com

Authorised by Mr. James Bonnar, Managing Director and CEO on behalf of the Board.

Investor & Media Enquiries:
Dimitri Burshtein
T: 0491 789 391
E: info@nyrada.com

Company Secretary:
David Franks
T: 02 8072 1400
E: David.Franks@automicgroup.com.au

Forward-Looking Statements

This announcement may contain forward-looking statements. You can identify these statements by the fact they use words such as "aim", "anticipate", "assume", "believe", "continue", "could", "estimate", "expect", "intend", "may", "plan", "predict", "project", "should", "target", "will" or "would" or the negative of such terms or other similar expressions. Forward-looking statements are based on estimates, projections, and assumptions made by Nyrada about circumstances and events that have not yet taken place. Although Nyrada believes the forward-looking statements to be reasonable, they are not certain. Forward-looking statements involve known and unknown risks, uncertainties and other factors that are in some cases beyond the Company's control that could cause the actual results, performance, or achievements to differ materially from those expressed or implied by the forward-looking statement.

Results of Meeting

Nyrada Inc

Annual General Meeting

Thursday, 19 November 2026

Automic
GPO Box 5193, Sydney, NSW 2001
P 1300 288 664 (aus) or +61 (0)2 9698 5414 (world)
F +61 (0)2 8583 3040 E hello@automic.com.au
ABN 27 152 260 814

In accordance with section 251AA of the Corporations Act 2001, the following information is provided in relation to resolutions put to members at the meeting.

		Proxy Votes (as at proxy voting close)				Poll Results (if applicable)			Results
Resolution	**Decided by Show of Hands (S) or Poll (P)**	**FOR**	**AGAINST**	**ABSTAIN**	**PROXY'S DISCRETION**	**FOR**	**AGAINST**	**ABSTAIN**	**OUTCOME**
1 Re-election of Mr. John Moore as Director	P	106,288,412 99.87%	0 0.00%	865,405	143,553 0.13%	108,741,251 100.00%	0 0.00%	865,405	Carried
2 Re-election of Mr. Christopher Cox as Director	P	105,720,198 99.86%	0 0.00%	1,433,619	143,553 0.14%	108,173,037 100.00%	0 0.00%	1,433,619	Carried
3 Re-election of Dr. Ian Dixon as Director	P	64,369,081 99.78%	0 0.00%	42,784,736	143,553 0.22%	66,821,920 100.00%	0 0.00%	42,784,736	Carried
4 Re-election of Mr. Marcus Frampton as Director	P	107,126,317 99.87%	0 0.00%	27,500	143,553 0.13%	109,579,156 100.00%	0 0.00%	27,500	Carried
5 Re-election of Dr. Rüdiger Weseloh as Director	P	105,633,517 99.86%	0 0.00%	1,520,300	143,553 0.14%	108,086,356 100.00%	0 0.00%	1,520,300	Carried
6 Re-election of Mr. James Bonnar as Director	P	107,105,943 99.87%	0 0.00%	47,874	143,553 0.13%	109,558,782 100.00%	0 0.00%	47,874	Carried
7 ASX Listing Rule 7.1A Approval of Future Issue of Securities	P	105,240,044 98.21%	1,719,910 1.61%	143,863	193,553 0.18%	107,742,883 98.43%	1,719,910 1.57%	143,863	Carried
8 Approval of Issue of Incentive Securities to Mr. John Moore, Chair and Director of the Company	P	82,608,818 97.43%	1,988,360 2.35%	9,824,562	193,553 0.23%	85,111,657 97.72%	1,988,360 2.28%	9,824,562	Carried
9 Approval of Issue of Incentive Securities to Mr. Christopher Cox, Director of the Company	P	82,608,818 97.43%	1,988,360 2.35%	9,824,562	193,553 0.23%	85,111,657 97.72%	1,988,360 2.28%	9,824,562	Carried

		Proxy Votes (as at proxy voting close)				Poll Results (if applicable)			Results
Resolution	**Decided by Show of Hands (S) or Poll (P)**	**FOR**	**AGAINST**	**ABSTAIN**	**PROXY'S DISCRETION**	**FOR**	**AGAINST**	**ABSTAIN**	**OUTCOME**
10 Approval of Issue of Incentive Securities to Dr. Ian Dixon, Director of the Company	P	67,016,485 79.04%	17,580,693 20.73%	9,824,562	193,553 0.23%	69,519,324 79.82%	17,580,693 20.18%	9,824,562	Carried
11 Approval of Issue of Incentive Securities to Mr. Marcus Frampton, Director of the Company	P	82,608,818 97.43%	1,988,360 2.35%	9,824,562	193,553 0.23%	85,111,657 97.72%	1,988,360 2.28%	9,824,562	Carried
12 Approval of Issue of Incentive Securities to Dr. Rüdiger Weseloh, Director of the Company	P	82,815,141 97.67%	1,782,037 2.10%	11,307,894	193,553 0.23%	85,317,980 97.95%	1,782,037 2.05%	11,307,894	Carried
13 Approval of Issue of Incentive Securities to Mr James Bonnar, Director of the Company	P	82,658,818 97.49%	1,988,360 2.35%	9,824,562	143,553 0.17%	85,111,657 97.72%	1,988,360 2.28%	9,824,562	Carried
14 Amendment to Bylaws for Directors Elections	P	106,210,645 99.04%	839,309 0.78%	53,863	193,553 0.18%	108,713,484 99.23%	839,309 0.77%	53,863	Carried
15 Amendment to Bylaws to Increase the Equity Incentive Plan Issue Cap under Section 1100V of the Corporations Act	P	106,036,807 99.02%	952,510 0.89%	214,500	93,553 0.09%	108,439,646 99.13%	952,510 0.87%	214,500	Carried